How big is PetMed Express, Inc.?

As of Jun 18, PetMed Express, Inc. has a market capitalization of 72.09 million, with net sales of 247.00 million and a net profit of 0.35 million over the last four quarters. Shareholder's funds are reported at 96.73 million, and total assets amount to 175.09 million as of Mar 24.

As of Jun 18, PetMed Express, Inc. has a market capitalization of 72.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 247.00 million, while the sum of net profit for the same period is 0.35 million.<BR><BR>As of Mar 24, the shareholder's funds are reported at 96.73 million, and total assets amount to 175.09 million.

What does PetMed Express, Inc. do?

PetMed Express, Inc. (1800PetMeds) is a pet pharmacy that sells prescription and non-prescription medications and health products for dogs and cats. As of December 2024, it reported net sales of $53 million and a net profit of -$1 million, with a market cap of $72.09 million.

Overview:<BR>PetMed Express, Inc., operating as 1800PetMeds, is a pet pharmacy that markets prescription and non-prescription pet medications and health products for dogs and cats, belonging to the retailing industry with a micro-cap market.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 53 Million (Quarterly Results - Dec 2024)<BR>- Most recent Net Profit: -1 Million (Quarterly Results - Dec 2024)<BR>- Market-cap: USD 72.09 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 82.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.52<BR>- Return on Equity: 0.29%<BR>- Price to Book: 0.75<BR><BR>Contact Details:<BR>- Address: 420 S Congress Ave, DELRAY BEACH FL: 33445-4693<BR>- Tel: 1 561 4264444<BR>- Website: https://www.1800petmeds.com/

Should I buy, sell or hold PetMed Express, Inc.?

Who are in the management team of PetMed Express, Inc.?

As of March 2022, the management team of PetMed Express, Inc. includes Mr. Robert Schweitzer (Independent Chairman), Mr. Menderes Akdag (President and CEO), and five independent directors: Ms. Leslie Campbell, Mr. Frank Formica, Dr. Gian Fulgoni, and Mr. Ronald Korn. They oversee the company's operations and strategic direction.

As of March 2022, the management team of PetMed Express, Inc. includes:<BR><BR>- Mr. Robert Schweitzer, Independent Chairman of the Board<BR>- Mr. Menderes Akdag, President, Chief Executive Officer, and Director<BR>- Ms. Leslie Campbell, Independent Director<BR>- Mr. Frank Formica, Independent Director<BR>- Dr. Gian Fulgoni, Independent Director<BR>- Mr. Ronald Korn, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is PetMed Express, Inc. overvalued or undervalued?

As of May 21, 2025, PetMed Express, Inc. is fairly valued with a P/E ratio of 82, lagging behind peers like Build-A-Bear Workshop at 12.51, and has underperformed the S&P 500 with a year-to-date return of -32.37%.

As of 21 May 2025, the valuation grade for PetMed Express, Inc. has moved from attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 82, an EV to EBITDA of 4.32, and a Price to Book Value of 0.85. <BR><BR>In comparison to peers, PetMed Express has a P/E ratio of 72.09, while Build-A-Bear Workshop, Inc. stands out with a very attractive P/E of 12.51, indicating a significant valuation gap. America's Car-Mart, Inc. also reflects a fair valuation with a P/E of 42.64. Notably, PetMed's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -32.37% compared to the index's 2.44%, further emphasizing its current valuation status.

Is PetMed Express, Inc. technically bullish or bearish?

As of September 8, 2025, PetMed Express, Inc. is in a bearish trend with weak momentum, reflected by bearish MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -41.91%.

As of 8 September 2025, the technical trend for PetMed Express, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and moving averages both showing bearish signals. The Bollinger Bands also reflect a bearish sentiment on the monthly timeframe. The stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -41.91% compared to the S&P 500's 12.22%.